PATENT CLAIM ANALYSIS

Application Number: 16029136
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "563000"]

Abstract:
Provided is an application of tranilast in the preparation of a medicament for treating scleredema diabeticorum. Tranilast was originally used clinically for the treatment of allergic diseases and keloids, which is a safe and effective medicament with few adverse reactions that has been used clinically for many years, it is currently used in patients with scleredema diabeticorum who have no definite therapeutic schedule, and after 3 months of application, the symptoms may be observed to be significantly relieved in clinical practice, the thickness of the skin was significantly thinner detected by B-ultrasound and no significant adverse reactions were observed. This suggests that the medicament can quickly control the skin lesions of the patients with scleredema diabeticorum, reduce the clinical symptoms, and has good tolerance, high patient compliance, rare adverse reactions, and good clinical efficacy and safety.

Claim (Index 3):
The method according to  claim 1 , wherein the subject has been diagnosed with scleredema diabeticorum.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.79518
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13378481', '11990583', '15852977', '14086785', '14673259']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7524150862646926
- 35 USC 102 Novelty (BERT): 0.4919102455939521
- Combined Prediction Score: 0.7263646021976184
- Mean Citation Score: 160.81663599999996
- Max Citation Score: 176.44856
- Similarity Product: 115.83463768167016

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test